RECRUITING

Long-term Result of DTPA (Diethylenetriamine Pentaacetate) Chelation for Gadolinium Deposition Disease

Talk to us

Conditions

Gadolinium Deposition DiseaseCa-DTPADTPA, chelation

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is aimed at describing the degree of benefit, if any, and the adverse effects, if any, from receiving 5 or more treatment sessions of Gadolinium Deposition Disease using two-day chelation treatment with the chelating agents Calcium Diethylenetriamine pentaacetate (Ca-DTPA) and Zinc Diethylenetriamine pentaacetate (Zn-DTPA).

Official Title

Long-term Result of DTPA Chelation for Gadolinium Deposition Disease

Quick Facts

Study Start:2024-12-02
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06269055

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Age 18 or older,
  2. 2. Diagnosis of Gadolinium Deposition Disease (GDD) established by treating MD according to current criteria and confirmed by investigator review of screening questionnaire (dx criteria: presence of at least 3 of 8 symptoms-cognitive disturbance, extremity pain, arthralgia, chest wall pain, skin pain, headache, skin induration, and skin hyperpigmentation; and, had an unprovoked 24-hour Gd urine excretion level exceeding the laboratory norm at least 28 days after the symptom-inducing MRI;
  3. 3. has had five or more 2-day chelation treatments with Ca-DTPA/Zn-DTPA;
  4. 4. will be at least 2 weeks post the last chelation treatment at the time of completing the patient data-gathering questionnaires.
  5. 5. no more than 2 years have elapsed since the last DTPA chelation.
  1. 1. Not fluent in written and spoken English; 2. having impaired hearing that significantly decreases the person's ability to communicate via telephone; 3. Prisoners; 4. Unable to provide informed consent; 5. Participating or having participated in protocols involving a pharmacological treatment of GDD other than DTPA chelation. Note: brief pre- or post-DTPA chelation to prevent GDD symptom flare is not an exclusion criterion.

Contacts and Locations

Study Contact

Lorrin M Koran, MD
CONTACT
650 321-6804
lkoran@stanford.edu
Jarrod Ehrie, MD
CONTACT
678-232-0624
ehrie@stanford.ecu

Study Locations (Sites)

Stanford University Medical Center
Stanford, California, 94305
United States

Collaborators and Investigators

Sponsor: Stanford University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-02
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2024-12-02
Study Completion Date2025-12-31

Terms related to this study

Keywords Provided by Researchers

  • DTPA, chelation

Additional Relevant MeSH Terms

  • Gadolinium Deposition Disease
  • Ca-DTPA